{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:52:09Z","timestamp":1791460329767,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yrtph.2026.106190","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:54:26Z","timestamp":1785455666000},"page":"106190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nonclinical safety profile for DCR-AUD GalNAc-conjugated siRNA: Subchronic versus chronic findings in mouse and non-human primate"],"prefix":"10.1016","volume":"172","author":[{"given":"Laura","family":"Sanftner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Kovalenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Diglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Landrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utsav","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7022-2637","authenticated-orcid":false,"given":"Girish","family":"Chopda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barent","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yrtph.2026.106190_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/nat.2024.0090","article-title":"Mechanistic insights into hybridization-based off-target activity of GalNAc-siRNA conjugates","volume":"35","author":"Agarwal","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2024.0072","article-title":"Assessing hybridization-dependent off-target risk for therapeutic oligonucleotides: updated industry recommendations","volume":"35","author":"Andersson","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40262-025-01606-0","article-title":"Platform assessment of Concentration-QTc relationship across GalNAc-siRNA molecules","volume":"65","author":"Badri","year":"2026","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106190_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/nat.2023.0011","article-title":"OSWG recommended approaches to the nonclinical pharmacokinetic (ADME) characterization of therapeutic oligonucleotides","volume":"33","author":"Berman","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/nat.2015.0534","article-title":"OSWG recommendations for genotoxicity testing of novel oligonucleotide-based therapeutics","volume":"26","author":"Berman","year":"2016","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"issue":"8","key":"10.1016\/j.yrtph.2026.106190_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.yrtph.2026.106190_bib10","article-title":"Receipt of services for behavioral health problems: results from the 2014 national survey on drug use and health","author":"Han","year":"2015","journal-title":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/019262339902700117","article-title":"Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1","volume":"27","author":"Henry","year":"1999","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106190_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vascn.2013.10.005","article-title":"Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies","volume":"69","author":"Kim","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","article-title":"Adoption and implementation of medications in addiction treatment programs","volume":"5","author":"Knudsen","year":"2011","journal-title":"J. Addiction Med."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"issue":"8","key":"10.1016\/j.yrtph.2026.106190_bib18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40265-025-02203-y","article-title":"Fitusiran: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.yrtph.2026.106190_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/em.70004","article-title":"Review of transcriptomic biomarkers that predict in vitro genotoxicity in human cell lines","volume":"66","author":"Li","year":"2025","journal-title":"Environ. Mol. Mutagen."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/acer.12193","article-title":"Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs","volume":"38","author":"Litten","year":"2014","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1472-8206.2002.00084.x","article-title":"Integration of safety pharmacology endpoints into toxicology studies","volume":"16","author":"Luft","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106190_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-Acetylgalactosamine-Conjugated small interfering RNA are highly predictable and build confidence in translation to human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.yrtph.2026.106190_bib22","series-title":"Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals","year":"2010"},{"issue":"8","key":"10.1016\/j.yrtph.2026.106190_bib24","first-page":"548","article-title":"FDA approves fifth RNAi drug - alnylam's next-gen hATTR treatment","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0300985811415701","article-title":"Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach","volume":"49","author":"Pandher","year":"2012","journal-title":"Vet. Pathol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/nat.2024.0075","article-title":"Opportunities for more tailored approaches to genotoxicity testing and carcinogenicity strategy for oligonucleotide therapeutics: outcome of an industry survey","volume":"35","author":"Parry","year":"2025","journal-title":"Nucleic Acid Therapeut."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106190_bib30","first-page":"463","article-title":"Involvement of acetaldehyde for full protection against alcoholism by homozygosity of the variant allele of mitochondrial aldehyde dehydrogenase gene in Asians","volume":"9","author":"Peng","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.yrtph.2026.106190_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105339","article-title":"The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain","volume":"138","author":"Prior","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cpt.3204","article-title":"Scientific review of the proarrhythmic risks of oligonucleotide therapeutics: are dedicated ICH S7B\/E14 studies needed for low-risk modalities?","volume":"116","author":"Qu","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.yrtph.2026.106190_bib33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfac067","article-title":"Preclinical toxicological assessment of A novel siRNA, SLN360, targeting elevated Lipoprotein (a) in cardiovascular disease","volume":"189","author":"Rider","year":"2022","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfac067","article-title":"Preclinical toxicological assessment of a novel siRNA, SLN360, targeting elevated lipoprotein (a) in cardiovascular disease","volume":"189","author":"Rider","year":"2022","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106190_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106190_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.yrtph.2014.07.018","article-title":"Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials","volume":"70","author":"Sewell","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0022-2836(81)90087-5","article-title":"Identification of common molecular subsequences","volume":"147","author":"Smith","year":"1981","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106190_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106190_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/nat.2019.0796","article-title":"Nonclinical safety profile of Revusiran, a 1st-Generation GalNAc-siRNA conjugate for treatment of hereditary transthyretin-mediated amyloidosis","volume":"30","author":"Sutherland","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"issue":"18","key":"10.1016\/j.yrtph.2026.106190_bib42","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:04:04Z","timestamp":1791457444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S0273230026001637"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106190","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical safety profile for DCR-AUD GalNAc-conjugated siRNA: Subchronic versus chronic findings in mouse and non-human primate","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106190"}}